SS&C Increases Common Stock Dividend 11.1% to $1.20 Annually

WINDSOR, Conn.–(BUSINESS WIRE)–SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced its Board of Directors has approved a dividend of $1.20 per share annually, an 11.1% increase from the prior annual rate. The next quarterly dividend of $0.30 per share will be paid on September 15, 2026, to stockholders of record as of the close of business on September 1, 2026.

SSNC Logo
SSNC Logo

Bill Stone, Chairman and CEO, commented: “Today’s dividend increase reflects the strength and consistency of our cash flow. We generated $716.4 million of net cash from operating activities in the first half of 2026, up 11.1% year over year. This strong cash flow gives us the flexibility to raise our dividend while continuing to repurchase shares, pay down debt and pursue high-quality acquisitions. With strong sales, high retention rates and steady margin expansion, we see significant opportunity ahead. We remain committed to disciplined capital allocation.”

About SS&C Technologies

SS&C is a leading provider of mission-critical, AI-powered technology and services that help financial services and healthcare organizations operate smarter, faster, and more securely. Founded in 1986, SS&C is headquartered in Windsor, Connecticut, and has offices worldwide. More than 23,000 financial services and healthcare organizations, from the world’s largest companies to small and mid-market firms, rely on SS&C for expertise, scale and technology. Additional information about SS&C (Nasdaq: SSNC) is available at www.ssctech.com.

SOURCE: SS&C

Additional information about SS&C (Nasdaq: SSNC) is available at www.ssctech.com.

Follow SS&C on X, LinkedIn and Facebook.

Contacts

Brian Schell | Chief Financial Officer, SS&C Technologies

Tel: +1-816-642-0915 | E-mail: [email protected]

Justine Stone | Investor Relations, SS&C Technologies

Tel: +1-212-367-4705 | E-mail: [email protected]

Chand Madaka │ Investor Relations, SS&C Technologies

Tel: +1-908-845-1259 │ E-mail: [email protected]

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Stay up-to-date with the latest Newsletters, free of charge.